SCHEMBL15215744

SCHEMBL15215744

Cc1nc(=O)c(Cc2ccccc2)c[nH]1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.54
ADORA1 P30542 2/20 0.54
PNP P00491 1/20 0.47
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
MET P08581 1/20 0.43
KDR P35968 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
DHFR P00374 1/20 0.40
DAO P14920 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
PLA2G7 Q13093 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10048197 0.80 ADORA2A (0.50) ADORA2AADORA1PNPKMT2AMEN1
SCHEMBL9904902 0.79 PLA2G7 (0.43) ADORA2AADORA1PNPPLA2G7
SCHEMBL82538 0.75 TAAR1 (0.43) ADORA2AADORA1KMT2AMEN1SMN1; SMN2
SCHEMBL4523968 0.75 POLB (0.43) KMT2AMEN1SMN1; SMN2DAO
SCHEMBL7007073 0.75 PLA2G7 (0.49) ADORA2AADORA1PNPSMN1; SMN2DAO
Water SCHEMBL10981448 0.74 TAAR1 (0.42) ADORA2AADORA1SMN1; SMN2TAAR1
SCHEMBL14942695 0.73 ALKBH3 (0.45) KMT2AMEN1SMN1; SMN2CYP3A4CYP2D6
SCHEMBL17139842 0.73 PNP (0.71) PNPKDR
Fluoride SCHEMBL28059937 0.72 TAAR1 (0.41) ADORA2AADORA1KMT2AMEN1SMN1; SMN2
SCHEMBL13244912 0.70 PDE5A (0.49) ADORA2AADORA1PNPKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604260-B1 NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME SHIONOGI & CO (JP) 2017-05-10 EP disclosed
US-9212130-B2 Heterocyclic derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2015-12-15 US disclosed
US-20130225596-A1 NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) SHIONOGI & CO., LTD. (JP) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225596-A1 NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) P2RX3, P2RX6, P2RX2 ADORA2A 36/4885ADORA1 30/4885PNP 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.